Phase 3 Study for Agitation in Alzheimer's Disease
This study, called ADAGIO-2, is looking at a treatment for agitation (restlessness or distress) in people with Alzheimer's disease. Researchers want to see how safe and effective two medications, KarXT + KarX-EC, are compared to a placebo (an inactive substance). You might be able to join if you are 55 to 90 years old, have an Alzheimer's diagnosis, and have specific evidence of Alzheimer's disease in your body, such as from a PET scan or spinal fluid tests. The main goal is to see if these medications reduce agitation after 14 weeks, measured by a special questionnaire. The study plans to enroll 352 people, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It is a Phase 3 study and plans to include 352 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at Week 14, indicating follow-up for at least that duration.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
At a glance
Conditions
Where it's being run
144 sites across 68 statesStudy leadership
- Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Change from baseline on the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association (CMAI-IPA) total score at Week 14At Week 14